المؤلفون: Terasaki H; Department of Ophthalmology, Nagoya University Hospital, Nagoya, Japan., Shiraki K; Department of Ophthalmology and Visual Sciences, Osaka City University, Osaka, Japan., Ohji M; Department of Ophthalmology, Shiga University of Medical Science, Otsu, Japan., Metzig C; Bayer AG, Berlin, Germany., Schmelter T; Bayer AG, Berlin, Germany., Zeitz O; Bayer AG, Berlin, Germany., Sowade O; Bayer AG, Berlin, Germany., Kobayashi M; Bayer Pharmaceuticals, Osaka, Japan., Vitti R; Regeneron Pharmaceuticals, Tarrytown, New York., Berliner A; Regeneron Pharmaceuticals, Tarrytown, New York., Shiraga F; Department of Ophthalmology, Okayama University Medical School, Okayama, Japan.

المصدر: Retina (Philadelphia, Pa.) [Retina] 2019 May; Vol. 39 (5), pp. 938-947.

نوع المنشور: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial

بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 8309919 Publication Model: Print Cited Medium: Internet ISSN: 1539-2864 (Electronic) Linking ISSN: 0275004X NLM ISO Abbreviation: Retina Subsets: MEDLINE

مواضيع طبية MeSH: Visual Acuity*, Diabetic Retinopathy/*drug therapy , Macula Lutea/*pathology , Macular Edema/*drug therapy , Receptors, Vascular Endothelial Growth Factor/*administration & dosage , Recombinant Fusion Proteins/*administration & dosage, Aged ; Diabetic Retinopathy/complications ; Dose-Response Relationship, Drug ; Double-Blind Method ; Female ; Follow-Up Studies ; Humans ; Intravitreal Injections ; Japan ; Macular Edema/etiology ; Male ; Middle Aged ; Receptors, Vascular Endothelial Growth Factor/antagonists & inhibitors ; Treatment Outcome